Fernandes, Executive Vice President, Chief Business Officer at Ipsen | Science rarely moves in a straight line. Philippe Lopes-Fernandes explores how an unexpected turn can reveal a credible path to ...

Moderna has scrapped plans to enroll a new cohort in a phase 3 trial of its norovirus vaccine and instead will meet with regulators to decide on next steps. | Moderna has scrapped plans to enroll a ...

Generate Biomedicines' CEO has hailed the “huge opportunity” offered by AI tools after the Flagship-founded company used ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

As biotech companies continue to navigate a challenging funding environment, Axiom Biosciences is taking an unconventional ...

Merck & Co. has called time on a Sutro Biopharma-partnered IL-2 agonist that was being tested for solid tumors, Fierce has ...

Siemens Healthineers will carve out its in vitro diagnostics business as a standalone company operating under the name ...

The aim is to reduce the biopharma’s R&D workforce by more than 35% compared with 2025 levels, with the associated cost ...

Evommune has agreed to pay $30 million to China’s Hinova Pharmaceuticals to get stuck into a niche of preclinical molecular ...

Vivoryon Therapeutics has regained the China rights to its kidney disease prospect as the German biotech’s cash reserves ...

Ultragenyx is laying off 20% of its workforce and axing drug development programs to cut its annual R&D budget to half of the ...

MetaVia has linked its GLP-1/glucagon receptor agonist to reductions in liver fat and body weight in a phase 1 trial.